该公司现有9项双盲、安慰剂对照、病人总数达650人的Ⅲ期临床试验正在英国和其他欧洲国家进行。另有2项针对多发硬化症特有症状,痉挛状态和膀胱机能障碍的Ⅲ期临床则刚刚开始。此外还有8个新大麻产品也要开始进入Ⅲ期临床研究。该公司称,4项进展最快的临床试验的病人征召数已完成了85％,生产及设备也已准备就绪,按计划,在英国 The company has nine double-blind, placebo-controlled Phase III clinical trials of 650 patients in the UK and other European countries. Another two phase III clinical trials have been just beginning for the specific symptoms of multiple sclerosis, spasticity and bladder dysfunction. In addition there are eight new cannabis products have begun to enter Phase Ⅲ clinical studies. The company said that the number of patient calls for the four fastest-growing clinical trials has been 85% complete, production and equipment ready, as planned, in the UK